Prognostic Parameters of Acute Myeloid Leukaemia at Presentation
- PMID: 28428668
- PMCID: PMC5364786
- DOI: 10.5455/medarh.2017.71.20-24
Prognostic Parameters of Acute Myeloid Leukaemia at Presentation
Abstract
Introduction: The treatment response and outcome in acute myeloid leukaemia (AML) is heterogeneous.
Aim: To analyze the prognostic parameters of AML at presentation.
Methods: The total sample of 44 AML patients was analyzed on the basis of age <55 and ≥55 years, sex, WBC count <50x10/9/l and ≥50x10/9/l, the Hb concentration <100 g/l and ≥100 g/l, PLT count <100x10/9/l and ≥100x10/9/l, Karnofsky score <60% and >60%, cytogenetics, CD56 expression, morphological type and types of treatment (standard and reduced induction chemotherapy, high-dose chemotherapy/stem cell transplantation - autologous and HLA matched, related, allogeneic, together and separately).
Results: The age <55 years, Karnofsky score >60% and standard induction chemotherapy statistically correlated with the higher complete remission (CR) rates, longer relapse free survival (RFS), lower relapse rate (RR), and longer overall survival (OS) (p<0.01). The difference in terms of CR and RR between the sexes were not statistically significant (p<0.05), however women had statistically lower OS comparing to men (9.71±4.54 months vs. 38.03±9.17 months) (p<0.01). WBC count ≥ 50x10/9/l and the Hb concentration <100 g/l statistically correlated with shorter OS (p<0.05), while the WBC count ≥50x10/9/l statistically correlated with shorter RFS (p<0.05). The PLT count <100x10/9/l and ≥100x10/9/l was not found as prognostically significant for CR, RR, RFS, and OS (p<0.05). In comparison to the standard induction chemotherapy, both types of high dose chemotherapy/stem cell transplantation (HDT/SCT) (10/22), together and separately, resulted in longer RFS, lower RR, and longer OS (p<0.05). The frequency of cytogenetic risk was intermediate 81.6%, unfavorable 13.2%, and favorable 5.3%, respectively. CD56 + expression statistically correlated with the lower PLT count, higher RR, shorter RFS, and shorter OS (p<0.05). Statistical analysis of the cytogenetic risk and morphological types of AML were not possible due to the small number of patients in stratified groups.
Conclusions: Female sex, the WBC count >50x10/9/l, the concentration of Hb <100 g/l, and CD56 + expression, at presentation of AML, should be considered as parameters of adverse risk, especially in latter decisions considering post-remission treatment with HDT/SCT.
Keywords: acute myeloid leukaemia; prognosis; prognostic parameter.
Conflict of interest statement
• Conflict of interest: none declared.
Figures
Similar articles
-
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.J Clin Oncol. 2011 Jun 20;29(18):2507-13. doi: 10.1200/JCO.2010.34.2873. Epub 2011 May 9. J Clin Oncol. 2011. PMID: 21555694 Free PMC article. Clinical Trial.
-
Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.Ann Hematol. 2003 Nov;82(11):684-90. doi: 10.1007/s00277-003-0730-1. Epub 2003 Aug 19. Ann Hematol. 2003. PMID: 12928754 Clinical Trial.
-
Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission.Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):444-51. doi: 10.1016/j.clml.2012.07.004. Epub 2012 Sep 20. Clin Lymphoma Myeloma Leuk. 2012. PMID: 22999942
-
Postremission therapy in adults with acute myeloid leukemia.Semin Hematol. 2001 Jul;38(3 Suppl 6):17-23. doi: 10.1016/s0037-1963(01)90152-0. Semin Hematol. 2001. PMID: 11474493 Review.
-
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.Am J Hematol. 2023 Sep;98(9):1383-1393. doi: 10.1002/ajh.26997. Epub 2023 Jun 19. Am J Hematol. 2023. PMID: 37334870 Free PMC article. Review.
Cited by
-
The proto-oncogenic miR-106a-363 cluster enhances adverse risk acute myeloid leukemia through mitochondrial activation.Leukemia. 2025 May;39(5):1090-1101. doi: 10.1038/s41375-025-02558-x. Epub 2025 Mar 17. Leukemia. 2025. PMID: 40097604
-
Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival.Cancer Med. 2023 Mar;12(6):6711-6721. doi: 10.1002/cam4.5461. Epub 2022 Nov 23. Cancer Med. 2023. PMID: 36419242 Free PMC article.
-
Androgen Therapy for Acute Myeloid and Hairy Cell Leukemia.Curr Treat Options Oncol. 2018 Jan 23;19(1):4. doi: 10.1007/s11864-018-0519-z. Curr Treat Options Oncol. 2018. PMID: 29362898 Review.
-
Prognostics and Clinical Outcomes in Patients Diagnosed With Acute Myeloid Leukemia (AML) in a Teaching Hospital.Cureus. 2021 Oct 20;13(10):e18915. doi: 10.7759/cureus.18915. eCollection 2021 Oct. Cureus. 2021. PMID: 34812301 Free PMC article.
-
Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review).Int J Oncol. 2024 Dec;65(6):112. doi: 10.3892/ijo.2024.5700. Epub 2024 Oct 4. Int J Oncol. 2024. PMID: 39364739 Free PMC article. Review.
References
-
- Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics 1997-2002. Cancer Causes Control. 2008;19:379–390. - PubMed
-
- Yin JA, O¨Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML – 15 trial. Blood. 2012;120:2826–35. - PubMed
-
- Béné MC, Bernier M, Casasnovas RO, et al. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol. 2001;113:737–45. - PubMed
-
- Leone G, Mele L, Pulsoni A, Equitani F, Pagano L. The incidence of secondary leukemias. Haematologica. 1999;84(10):937–45. - PubMed
-
- Juliusson G, Antunovic P, Derolf A, Lehmann S, Mo¨llgård R, Stockelberg D, Tidefelt U, Wahlin A, Ho¨glund M. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–87. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous